STAT3 and non-Hodgkin lymphoma: Given that STAT3 binds to and inhibits Stathmin 1 in non-Hodgkin lymphoma and gastric cancer human cell lines [13, 14], we first confirmed the association of STAT3 and Stathmin 1 in HEL cells, which was abrogated by ruxolitinib treatment (Figure 1A), possibly due to STAT3 phosphorylation inhibition induced by ruxolitinib [15].